Physician profile
Robert Levin
NPI 1932186467
$3,265.53
in general payments reported to CMS, 2019-2025
42 companies · $1,692 in 2025
The $1,692 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $48.66 · 2021: $112 · 2022: $217 · 2023: $333 · 2024: $738 · 2025: $1,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,589 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,588.61 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $375.94 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $315.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $186.20 | 2024-2025 | Enhertu, Wainua, Lynparza |
| Array Biopharma INC | $184.99 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Sun Pharmaceutical Industries INC. | $173.05 | 2024-2025 | |
| Daiichi Sankyo INC. | $108.22 | 2024-2025 | Enhertu |
| Global Blood Therapeutics, INC. | $107.46 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $105.51 | 2019-2023 | Opdivo |
| Stemline Therapeutics INC. | $105.12 | 2024-2025 | Orserdu, Elzonris |
| Seagen INC. | $99.00 | 2025 | |
| Celgene Corporation | $97.20 | 2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $94.53 | 2022-2023 | Keytruda |
| Janssen Biotech, INC. | $94.08 | 2024 | Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $91.28 | 2023-2025 | Iclusig, Fruzaqla |
| Pharmaessentia USA Corporation | $82.71 | 2025 | Besremi |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.